Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.67 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706467 | 1.00 | HCRTR1 (0.67) | HCRTR1HCRTR2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL7683521 | 0.83 | MMP1 (0.56) | HCRTR1HCRTR2KMT2AGPBAR1TSHR | |
| SCHEMBL7683529 | 0.83 | MMP1 (0.56) | HCRTR1HCRTR2KMT2AGPBAR1TSHR | |
| SCHEMBL2705860 | 0.83 | MMP1 (0.67) | HCRTR1HCRTR2ALDH1A1HTTTSHR | |
| SCHEMBL2706480 | 0.83 | MMP1 (0.67) | HCRTR1HCRTR2ALDH1A1HTTTSHR | |
| SCHEMBL2705855 | 0.83 | MMP1 (0.67) | HCRTR1HCRTR2ALDH1A1HTTTSHR | |
| SCHEMBL2707087 | 0.81 | HCRTR1 (0.64) | HCRTR1HCRTR2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL2707091 | 0.81 | HCRTR1 (0.64) | HCRTR1HCRTR2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL2706977 | 0.80 | HCRTR1 (0.71) | HCRTR1HCRTR2HTTKMT2ATSHR | |
| SCHEMBL2706982 | 0.80 | HCRTR1 (0.71) | HCRTR1HCRTR2HTTKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2608787-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-07-03 | — | — | EP | claimed |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-13 | — | — | US | claimed |
| CN-103079563-A | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2013-05-01 | — | — | CN | claimed |
| WO-2012025877-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-03-01 | — | — | WO | claimed |
| EP-2608787-B1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-9211279-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-03 | — | — | US | disclosed |
| CN-103079563-B | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2015-07-08 | — | — | CN | disclosed |
| US-9000029-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-02-26 | — | — | US | disclosed |
| US-8895606-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2608787-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-13 | — | — | US | disclosed |
| CN-103079563-A | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2013-05-01 | — | — | CN | disclosed |
| WO-2012025877-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | HCRTR1 2/4885HCRTR2 1/4885KDM4E 3175/4885 |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | HCRTR1 2/4885HCRTR2 1/4885KDM4E 3175/4885 |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | HCRTR1 2/4885HCRTR2 1/4885KDM4E 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.